ArticleFrontiers in immunology2025
Idiopathic inflammatory myopathy associated with Sjögren's disease: features of a distinct clinical entity.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- [Sjögren's disease : Manifestations in peripheral nerves].Zeitschrift fur Rheumatologie · 2026Review
- Idiopathic Inflammatory Myopathies-Treatment Perspective of Highly Specialised Rheumatology Centre.Journal of clinical medicine · 2026Article
- The Role of Imaging Techniques in the Evaluation of Extraglandular Manifestations in Patients with Sjögren's Syndrome.Diagnostics (Basel, Switzerland) · 2026Review
- Antibodies against Ro52 in idiopathic inflammatory myopathies are associated with objective sicca symptoms.Frontiers in immunology · 2026Article
- Muscular involvement in Sjögren's disease is associated with male gender, Ro52 autoantibodies, and a higher clinical activity.Frontiers in medicine · 2026Article
- Interstitial Lung Disease Secondary to Sjogren's Syndrome and Antisynthetase Syndrome: Converging Disease Trajectories.Medicina (Kaunas, Lithuania) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Idiopathic inflammatory myopathies (IIM) and Sjögren's disease (SjD) may coexist, but data on their combined presentation and treatment response remain limited. Methods: We retrospectively analyzed 23 patients with biopsy-confirmed IIM and coexisting SjD, compared to 24 age- and sex-matched IIM controls without SjD. Clinical, electrophysiological, and immunological data, as well as treatments and outcomes, were assessed. Outcome assessment included EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI) and the ACR/EULAR Myositis Response Criteria for adult polymyositis and dermatomyositis. Results: Among IIM-SjD patients, 39% had inclusion body myositis (IBM), 61% had poly- or dermatomyositis. Compared to controls, asymmetric muscle weakness (78%, p=0.0012), non-muscular manifestations (52%, p=0.0035), and more immunosuppressive therapies (median 3; p=0.0253), including more frequent anti-CD20 use (30%, p=0.0039) were found in IIM-SjD. After a median follow-up of 80 months, patients showed better outcomes (lower ESSDAI and higher ACR/EULAR response scores; p=0.0031 and p=0.0083). IBM was a strong predictor of higher ESSDAI scores at follow-up (p=0.014). Conclusions: The study suggests that IIM-SjD is characterized by more asymmetric muscle weakness and extramuscular involvement. Enhanced immunosuppression led to better outcomes in patients with poly- or dermatomyositis, while IBM was linked to higher disease activity. Further research is needed to clarify underlying mechanisms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.